TREATMENT OF HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA WITH PRAVASTATIN (CS-514) AND OR CHOLESTYRAMINE - (THE SPANISH MULTICENTER PRAVASTATIN STUDY)

被引：0
|
作者：
CARMENA, R
DEOYA, M
FRANCO, M
MARTINEZ, M
MATA, P
GOMEZ, J
SERRANO, S
ALVAREZSALA, L
MATESANZ, J
RUBIO, M
GRAS, X
机构：
来源：
ATHEROSCLEROSIS VIII | 1989年 / 817卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：757 / 760
页数：4
相关论文
共 50 条
  • [21] PRELIMINARY-RESULTS OF A DOUBLE-BLIND COMPARISON OF PRAVASTATIN AND CHOLESTYRAMINE IN FAMILIAL HYPERCHOLESTEROLEMIA
    BETTERIDGE, J
    BHATNAGAR, D
    DURRINGTON, P
    EVANS, G
    JAY, R
    LEWISBARNED, N
    MANN, J
    MATSAKIS, M
    MATTHEWS, D
    MILLER, P
    RECKLESS, J
    STURLEY, R
    TAYLOR, K
    WINDER, A
    ATHEROSCLEROSIS, 1989, 79 (01) : 96 - 96
  • [22] A MULTICENTER COMPARATIVE TRIAL OF LOVASTATIN AND PRAVASTATIN IN THE TREATMENT OF HYPERCHOLESTEROLEMIA
    FERDER, LF
    BERTOLAMI, MC
    GIANNINI, SD
    CORTAZAR, J
    OBONARELLANO, A
    AGNER, E
    LETH, A
    MATTILA, S
    TIKKANEN, MJ
    FRUCHART, JC
    DUTZ, W
    GUNTHER, KH
    GUTSCHKER, A
    HEINEMAN, G
    MORICKE, KR
    REUTER, W
    STEINHAGENTHIESSEN, E
    KRANKENHAUS, MB
    TOUTOUZAS, P
    TAI, YT
    RUBENSTEIN, A
    RULL, J
    OSE, L
    GARMENDIA, F
    CARRAGETA, MO
    MARTINSCORREIA, JF
    ALVAREZSALA, L
    GIMILIO, JA
    MELINO, MR
    MITCHEL, YB
    NG, J
    STEIN, E
    AMERICAN JOURNAL OF CARDIOLOGY, 1993, 71 (10): : 810 - 815
  • [23] COMBINATION TREATMENT WITH CHOLESTYRAMINE AND BEZAFIBRATE FOR HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA
    CURTIS, LD
    DICKSON, AC
    LING, KLE
    BETTERIDGE, J
    BRITISH MEDICAL JOURNAL, 1988, 297 (6642): : 173 - 175
  • [24] INDUCTION OF HEPATIC LDL RECEPTORS IN NORMAL AND HETEROZYGOUS WHHL RABBITS TREATED WITH CS-514 IN COMBINATION WITH CHOLESTYRAMINE
    KUME, N
    KITA, T
    ISHII, K
    NAGANO, Y
    YOKODE, M
    KAWAI, C
    JAPANESE CIRCULATION JOURNAL-ENGLISH EDITION, 1987, 51 (08): : 943 - 943
  • [25] Serum noncholesterol sterols in children with heterozygous familial hypercholesterolemia undergoing pravastatin therapy
    Hedman, M
    Miettinen, TA
    Gylling, H
    Ketomaki, A
    Antikainen, M
    JOURNAL OF PEDIATRICS, 2006, 148 (02): : 241 - 246
  • [26] A NOVEL-APPROACH TOWARDS THE STEREOSPECIFIC TOTAL SYNTHESIS OF PRAVASTATIN (CS-514) AND RELATED MEVINIC ACIDS AND ANALOGS
    EMONDS, MVM
    MARINO, JP
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 1992, 203 : 200 - MEDI
  • [27] One-year efficacy and safety of pravastatin in children and adolescents with heterozygous familial hypercholesterolemia
    Hedman, M
    Matikainen, T
    Föhr, A
    Lappi, M
    Piippo, S
    Nuutinen, M
    Antikainen, M
    EUROPEAN HEART JOURNAL, 2004, 25 : 37 - 38
  • [28] Efficacy and safety of pravastatin 40 mg day in Japanese patients with heterozygous familial hypercholesterolemia
    Mabuchi, H
    Matsuzawa, Y
    Saito, Y
    Gunji, A
    ATHEROSCLEROSIS, 1999, 144 : 194 - 194
  • [29] EFFECTS OF CS-514 ON SERUM-LIPOPROTEIN LIPID AND APOLIPOPROTEIN LEVELS IN PATIENTS WITH FAMILIAL HYPERCHOLESTEROLEMIA
    MABUCHI, H
    KAMON, N
    FUJITA, H
    MICHISHITA, I
    TAKEDA, M
    KAJINAMI, K
    ITOH, H
    WAKASUGI, T
    TAKEDA, R
    METABOLISM-CLINICAL AND EXPERIMENTAL, 1987, 36 (05): : 475 - 479
  • [30] MODULATION OF LDL PARTICLE HETEROGENEITY IN HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA BY AN HMGCOA REDUCTASE INHIBITOR, PRAVASTATIN
    CHAPMAN, MJ
    DAIROU, F
    GOULINET, S
    LAPLAUD, PM
    ARTERIOSCLEROSIS, 1990, 10 (05): : A836 - A837
12345